Moderna
MRNA
788 hedge funds and large institutions have $17.4B invested in Moderna in 2024 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 258 increasing their positions, 324 reducing their positions, and 218 closing their positions.
0.38% less ownership
Funds ownership: 68.39% → 68.01% (-0.38%)
17% less funds holding
Funds holding: 954 → 788 (-166)
20% less repeat investments, than reductions
Existing positions increased: 258 | Existing positions reduced: 324
36% less call options, than puts
Call options by funds: $926M | Put options by funds: $1.46B
44% less capital invested
Capital invested by funds: $31.1B → $17.4B (-$13.7B)
46% less funds holding in top 10
Funds holding in top 10: 13 → 7 (-6)
72% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 218
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$167M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$136M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$109M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$100M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$83.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$435M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$347M |
| 3 |
Morgan Stanley
New York
|
-$137M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$91M |
| 5 |
Goldman Sachs
New York
|
-$74.2M |
MRNA Hedge Fund Activity: Q3 2024 in Review
788 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q3 2024, worth a combined $17.4B — down 44% from $31.1B a quarter earlier.
Sellers outnumbered buyers: 218 funds closed out of MRNA and 61 opened new positions — a net loss of 157 holders — while 324 trimmed existing stakes and 258 added.
The largest buyer was State Street, adding an estimated $167M. The largest seller was Capital World Investors, exiting entirely with an estimated $435M sold.
- 788 institutional investors held Moderna (MRNA) as of Q3 2024, down from 954 in Q2 2024.
- Funds reported $17.4B of Moderna stock for Q3 2024, down 44% quarter-over-quarter.
- 61 funds opened new Moderna positions in Q3 2024 and 218 closed out, a net change of -157 holders.
- The largest Moderna buyer in Q3 2024 was State Street, an estimated $167M added.
- The largest Moderna seller in Q3 2024 was Capital World Investors, an estimated $435M sold.
Based on aggregated 13F filings for Q3 2024.